Key Market Indicator:
Ad-hoc news is mandatory information from listed companies that must be made available to investors. Depending on the occasion and content of the news, it can have an impact on the share price. The newsfeed covers a wide range of topics relevant to investor relations and is recommended as an important source of information before making an investment decision.
CH0210362643
Mon, 31.03.2025
BioVersys AG
Ad hoc announcement pursuant to Art. 53 LR
Basel, Switzerland. March 31, 2025, 7am CET
Important patent around BioVersys’ BV100 drug candidate has been granted, protecting the proprietary rifabutin IV formulation technology in China
BV100 patents have now been granted in over 25 countries, including in US, Europe, UK and China
BioVersys AG (SIX [ … ]
Wed, 26.03.2025
BioVersys AG
Ad hoc announcement pursuant to Art. 53 LR
Basel, Switzerland. March 26, 2025, 7am CET
BV100: Positive Phase 2 VABP trial read-out with excellent safety and efficacy data
Alpibectir: Phase 2a EBA trial delivered very strong proof of concept
Preclinical candidates from BioVersys’ two proprietary platforms continue to progress
Full Year 2024 oper [ … ]
Wed, 19.03.2025
BioVersys AG
Ad hoc announcement pursuant to Art. 53 LR
Basel, Switzerland. March 19, 2025, 7am CET. Ad hoc announcement pursuant to Art. 53 LR
Under the BioVersys and GSK collaboration agreement, GSK is evaluating the early bactericidal activity (EBA) of alpibectir-ethionamide (AlpE) in a pulmonary tuberculosis (TB) trial, in combination with first-line TB [ … ]
Mon, 10.03.2025
BioVersys AG
Ad hoc announcement pursuant to Art. 53 LR
Basel, Switzerland. March 10, 2025, 7am CET. Ad hoc announcement pursuant to Art. 53 LR
Partial exercise of over-allotment option following end of stablization period in context of the company’s initial public offering (IPO)
An additional 47,862 new shares to be issued by BioVersys
BioVersys raised tot [ … ]